



October 23, 2015

Galectin Therapeutics Selected to Present at Cavendish Global Health Impact Forum

Forum Uniquely Brings Together Leading Family Offices, Their Foundations and Sovereign Wealth Fund Representatives Seeking Impact Investment, Grant-Giving, and Philanthropy Opportunities Within Health and Life Sciences

NORCROSS, Ga., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25th to October 28th at The Cleveland Clinic in Cleveland, Ohio. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, research institutions, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.

Michael Moffat, Cavendish co-founder and chief executive officer explains, "The theme of our Cleveland Clinic hosted Forum is a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.' With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Galectin Therapeutics' research and scientific insights in fibrotic disease, including fatty liver disease and NASH (non-alcoholic steatohepatitis) and cancer, positions them to make a major contribution in the field of biotechnology."

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to fibrotic disease and cancer afflicting populations around the world today," said Jim Czirr, executive chairman of the board. "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of over 200 leading family offices and foundations from around the world with combined assets of over \$260 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations which they are passionate about with other family offices from around the world.

About Cavendish Global

<http://cavendishglobal.com>

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.

For more information: <http://cavendishglobal.com>

For Further Information Contact:

Alex Charlton
President, Cavendish Global
alex.charlton@cavendishglobal.com

Tel: +1-917-576-1435

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

CONTACT: Jack Callicutt, Chief Financial Officer

(678) 620-3186

ir@galectintherapeutics.com.

LHA

Kim Golodetz

(212) 838-3777

kgolodetz@lhai.com